Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Major Depression Clear all
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jun 27, 2026, 2:23 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 27, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional

Adaptive tDCS for Treatment-Resistant MDD

NCT02942368
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
tDCS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Recruiting Not applicable Interventional

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

NCT07217223
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Interventions
Spaced Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Recruiting Phase 4 Interventional

Establishing Mobile Transcranial Magnetic Stimulation

NCT06748209
View directory record Official record
Conditions
Treatment Resistant Major Depression
Interventions
Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Jun 27, 2026, 2:23 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Completed No phase listed Observational

The Treatment of Children and Adolescents With Treatment-Resistant Depression

NCT00029640
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 1 Interventional Results available

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine Infusion plus RO DBT
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Not listed Phase 2 Interventional

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

NCT04971291
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
AXS-05, Bupropion SR
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Jun 27, 2026, 2:23 AM EDT
Recruiting Not applicable Interventional

DBS for TRD With the Medtronic Percept PC

NCT05773755
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Percept PC DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Recruiting Not applicable Interventional

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

NCT05849402
View directory record Official record
Conditions
Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
Interventions
Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

AZD6765 for Treatment Resistant Depression

NCT00491686
View directory record Official record
Conditions
Depression
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Glendale, California • Hartford, Connecticut • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2011 · Synced Jun 27, 2026, 2:23 AM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for Depression and Suicide Risk

NCT02094898
View directory record Official record
Conditions
Depression, Suicide
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jun 27, 2026, 2:23 AM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Psilocybin for Treatment-Resistant Depression

NCT06230757
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions
Psilocybin 25mg, Placebo (active placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jun 27, 2026, 2:23 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

NCT06480201
View directory record Official record
Conditions
Healthy, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
21 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Suspended Not applicable Interventional

Low-Intensity Focused Ultrasound for Treatment-Resistant Depression

NCT06013384
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Low-Intensity Focused Ultrasound Pulsation, Sham Low-Intensity Focused Ultrasound Pulsation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jun 27, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 27, 2026, 2:23 AM EDT